Detailed price information for Rhythm Pharmaceuticals Inc (RYTM-Q) from The Globe and Mail including charting and trades.

New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related semaglutide-based drugs, Ozempic and Wegovy – since 2022 amid unprecedented ...

More than 15.5 million U.S. adults have been diagnosed with ADHD, and nearly three-quarters of those taking medication to ...

Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on ...

Meanwhile, cities in New Mexico, Minnesota, Kansas, and Utah are leading the pack for cities who are the most open to trying ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.